Bafna Pharmaceuticals — 360° view

Bafna Pharmaceuticals, a company in the Pharmaceuticals industry, reported revenue of ₹48 crore and net profit of ₹6.85 crore for the September 2026 quarter.

Bafna Pharmaceuticals (NSE: BAFNAPH-BE) closed at ₹469.95 on 20 Nov 2026. Its market capitalisation is ₹1,112 crore and it trades at 96.5 times earnings.

Share price
₹469.95 (20 Nov 2026)
Market cap
₹1,112 Cr (20 Nov 2026)
P/E
96.51 (20 Nov 2026)
Revenue
₹48 Cr (September 2026 quarter)
Net profit
₹7 Cr (September 2026 quarter)
ROCE
11.9% (FY26)
ROE
12.3% (FY26)
Book value
₹43.6 (FY26)
Dividend yield
0.00% (last 12 months to 20 Nov 2026)
52-week high / low
₹501.65 / ₹144.01 (20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: BAFNAPH-BE

Incorporated in 1981, Bafna Pharmaceuticals Ltd manufactures finished pharmaceutical formulations

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.